Last reviewed · How we verify
Postoperative adjuvant therapy for urothelial carcinoma
Approved treatments
- Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Postoperative adjuvant therapy for urothelial carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Postoperative adjuvant therapy for urothelial carcinoma treatment landscape brief
- Postoperative adjuvant therapy for urothelial carcinoma treatment updates RSS
Frequently asked questions about Postoperative adjuvant therapy for urothelial carcinoma
What drugs treat Postoperative adjuvant therapy for urothelial carcinoma?
Tracked treatments include Opdivo.
What is the treatment for Postoperative adjuvant therapy for urothelial carcinoma?
Standard treatment for Postoperative adjuvant therapy for urothelial carcinoma includes Opdivo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Postoperative adjuvant therapy for urothelial carcinoma patent cliff · Postoperative adjuvant therapy for urothelial carcinoma CI report
- Treatment: Opdivo · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing